Medifast Balance Sheet Health
Financial Health criteria checks 6/6
Medifast has a total shareholder equity of $207.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $291.2M and $83.9M respectively. Medifast's EBIT is $23.3M making its interest coverage ratio -4.6. It has cash and short-term investments of $170.0M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -4.6x |
| Cash | US$169.96m |
| Equity | US$207.34m |
| Total liabilities | US$83.90m |
| Total assets | US$291.24m |
Recent financial health updates
Recent updates
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Nov 06Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Sep 03Medifast Business Continues To Shrink, Stock Still Risky
Aug 27Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24
Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Medifast: Let's Dive Into Its Q2 Earnings And Assess The Bad And The Good
Aug 21Financial Position Analysis
Short Term Liabilities: MED's short term assets ($225.0M) exceed its short term liabilities ($72.4M).
Long Term Liabilities: MED's short term assets ($225.0M) exceed its long term liabilities ($11.5M).
Debt to Equity History and Analysis
Debt Level: MED is debt free.
Reducing Debt: MED had no debt 5 years ago.
Debt Coverage: MED has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: MED has no debt, therefore coverage of interest payments is not a concern.